Trial Profile
PERSEUS - A Prospective Non-interventional Study to Assess the Effectiveness of Aflibercept (Eylea) in Routine Clinical Practice in Patients With Wet Age-related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Sep 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms PERSEUS
- Sponsors Bayer
- 01 Aug 2021 Results published in the Graefes Archive for Clinical and Experimental Ophthalmology
- 16 Jun 2017 Status changed from active, no longer recruiting to completed.
- 01 Jun 2017 Planned primary completion date changed from 1 Mar 2017 to 30 Jun 2017.